Overview We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-basedtechnology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure ofurinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our appr...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001437749-26-006234 | EDGAR | 104K words |
| 2025-03-10 | 2024-12-31 | 0001437749-25-006842 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001437749-24-007753 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0001437749-23-007710 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001437749-22-006778 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-014016 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-007970 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005323 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001437749-25-033468 | EDGAR | 78K words |
| 2025-08-07 | 2025-06-30 | 0001437749-25-025243 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001437749-25-015956 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001437749-24-033454 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001437749-24-026161 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001437749-24-016116 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001437749-23-031766 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001437749-23-022879 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001437749-23-013767 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001437749-22-026727 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001437749-22-020131 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001437749-22-011618 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001437749-26-006233 | EDGAR | 5K words |
| 2026-03-02 | 0001193125-26-084282 | EDGAR | — |
| 2025-11-06 | 0001437749-25-033466 | EDGAR | — |
| 2025-08-27 | 0001437749-25-027874 | EDGAR | — |
| 2025-08-07 | 0001437749-25-025242 | EDGAR | — |
| 2025-07-03 | 0001193125-25-155503 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140339 | EDGAR | — |
| 2025-05-12 | 0001437749-25-015955 | EDGAR | — |
| 2025-03-10 | 0001437749-25-006757 | EDGAR | — |
| 2025-02-20 | 0001193125-25-030143 | EDGAR | — |
156 total filings indexed. 126 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001668243 |
| Ticker | URGN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | L3 |
| Website | https://www.urogen.com |
| Listed | 2017-05-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report